• About
  • Advertise
  • Careers
  • Write for us
  • Contact
  • Terms of service
No Result
View All Result
Saturday, March 6, 2021
THE MILLENNIAL SOURCE
  • World
  • US
  • Asia
  • Politics
  • Business
  • Profiles
  • Lifestyle
    • Food & Travel
    • Tech & Money
    • Health
    • Entertainment
  • Newsletter
TMS
No Result
View All Result
Home WORLD

Pfizer’s COVID-19 vaccine, explained

byMatthew Stafford
November 10, 2020
in WORLD
Reading Time: 5 minute read
Pfizer’s COVID-19 vaccine, explained

Source: Dado Ruvic, Reuters

Share on FacebookShare on TwitterShare on Linkedin
Though Pfizer’s trial results are undoubtedly good news, it will not bring the coronavirus pandemic to a sudden halt. People must remain vigilant and take precautions.

After a year in which most of the global community has had to learn – with varying degrees of success – to live with the COVID-19 pandemic, the first truly promising signs of a COVID-19 vaccine are beginning to show. 

American pharmaceutical giant Pfizer Inc., in collaboration with its German partner and vaccine developer BioNTech SE, has announced that the preliminary results of its vaccine show that it is more than 90% effective in preventing transmission of COVID-19 among trial volunteers. 

With no side-effects yet reported and an efficacy rate far above the 50% required for emergency authorization, Pfizer’s and BioNTech’s development is the first major breakthrough in the global race for a COVID-19 vaccine. 

Though Pfizer’s trial results are undoubtedly good news, it will not bring the coronavirus pandemic to a sudden halt. People must remain vigilant and take precautions.

The United States recently passed 10 million confirmed COVID-19 cases. With a widespread rollout of any potential vaccine still months away, the “very dark winter” highlighted by President-elect Joe Biden remains a very real possibility. 

Vaccine developments 

Pfizer and BioNTech’s potential coronavirus vaccine has made headlines around the world, offering hope that the end of the COVID-19 pandemic is in sight. 

A potential coronavirus vaccine was first put into development by the German company BioNTech in the city of Mainz in January, before the full extent of the coronavirus pandemic was known around the world. In March, BioNTech partnered with the American pharmaceutical giant Pfizer to begin human trials. 

Now, in a trial that consisted of nearly 44,000 participants around the world, BioNTech and Pfizer’s vaccine has displayed an efficacy rate of some 90%. This means that of those given the vaccine during the trial, relatively few contracted COVID-19. These results suggest that a wide rollout of the vaccine would yield positive results worldwide.

The US Food and Drug Administration (FDA) has instituted a bar of 50% for vaccine makers before any potential vaccines are eligible to be submitted for emergency authorization. The 90% efficacy rate displayed by Pfizer’s potential vaccine more than crosses this threshold.

Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, has hailed these results as “extraordinary.”

By the end of the year, Pfizer expects to have produced enough doses to immunize 15 to 20 million people, with the most vulnerable expected to receive the vaccine first. Nations around the world have already placed orders on Pfizer’s vaccine, with the US requesting 100 million doses. 

Experts cautioned that while Pfizer’s news is encouraging, it does not mean an end to the pandemic. Linda Selvey, an infectious diseases epidemiologist at the University of Queensland, Australia, told Bloomberg that the news “is very encouraging, however, it will not, on its own, mean that we will be able to resume ‘business as usual’ any time soon.”

Back into lockdown

However, news of Pfizer’s development comes at a time of little other good news regarding the coronavirus. 

Trials of other vaccines around the worlds have hit complications. In Brazil, trials of the CoronaVac vaccine, produced by Chinese company Sinovac Biotech Ltd., which is already being deployed in China, were halted after health authorities reported a “severe adverse” incident in October.

Nations around the world are also experiencing a resurgence of the virus as winter approaches. This has led countries to once again take stringent measures to deal with rising case numbers. 

The United Kingdom recently entered a second period of sustained lockdown while other European nations that haven’t already instituted similar lockdown measures are said to be considering them once more. 

In the US, the continued surge of coronavirus cases has belied President Donald Trump’s claim that after the election “you won’t hear anything about it because we’re rounding that turn.” 

Not only have COVID-19 cases in the US continued to grow, they never receded in the first place. The death toll in the US is now close to 240,000, with total cases in the country now over 10 million. Meanwhile, the average number of deaths in the US remains around 1,000 a day. 

While encouraging, full-scale vaccination, both in the US and globally, appears some time off.

High-risk members of the population will be first in line to receive any potential vaccine, which could happen before the end of the year. For the wider population, however, the availability of any potential COVID-19 vaccine could stretch into 2021. That’s if no complications arise in the meantime, which is not guaranteed. 

The worldwide rollout of the Pfizer and BioNTech vaccine is also uncertain. The vaccine needs to be kept at especially cold temperatures, which may pose logistical issues for many developing countries. 

Nonetheless, data from Pfizer’s trial is encouraging and signals that the world may be one step closer to finally seeing an end to the coronavirus pandemic.

Have a tip or story? Get in touch with our reporters at [email protected]

Like TMS? Subscribe to our free daily newsletter

Related

Tags: BusinessLonger readNorth America
ShareTweetShare

Latest Posts

After raising US$8.3 billion in loans, what’s Tencent going to do next?

After raising US$8.3 billion in loans, what’s Tencent going to do next?

March 4, 2021
How would Senator Elizabeth Warren’s 2% wealth tax work?

How would Senator Elizabeth Warren’s 2% wealth tax work?

March 4, 2021
The future of cryptocurrency

The future of cryptocurrency

March 3, 2021

After an ascendant 2020, New York Governor Andrew Cuomo is having a terrible 2021

March 3, 2021

The Biden administration’s changes to the Paycheck Protection Program

March 2, 2021

What are NFTs?

March 2, 2021

The Dasgupta Review offers economically viable solutions for combating climate change

March 2, 2021

Here are the biggest take-aways from CPAC 2021

March 1, 2021

LinkedIn is launching its own service for freelancers

March 1, 2021
  • About
  • Advertise
  • Careers
  • Write for us
  • Contact
  • Terms of service

© 2020 The Millennial Source Ltd.

No Result
View All Result
  • World
  • US
  • Asia
  • Politics
  • Business
  • Profiles
  • Lifestyle
    • Food & Travel
    • Tech & Money
    • Health
    • Entertainment
  • Newsletter

© 2020 The Millennial Source Ltd.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

The Millennial Source
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.